Table 4.

Multivariate Logistic Regression of the Association Between Polypharmacy and Multimorbidity Among Medicaid Enrollees (n = 38,329)

	Polypharmacy
	Definition 1	Definition 2	Definition 3
	AOR (95% CI)	AOR (95% CI)	AOR (95% CI)
Multimorbidity
2 conditions vs. 1	2.47 (2.33–2.61)	2.73 (2.44–3.05)	2.78 (2.63–2.94)
3 conditions vs. 1	4.59 (4.30–4.90)	5.84 (5.24–6.52)	6.07 (5.64–6.53)
≥4 conditions vs. 1	8.88 (8.28–9.51)	16.49 (14.87–18.29)	14.93 (13.65–16.34)
Age group
35–44 vs. 18–34	1.93 (1.78–2.10)	1.92 (1.65–2.23)	1.68 (1.55–1.81)
45–54 vs. 18–34	2.70 (2.51–2.90)	2.40 (2.09–2.75)	2.07 (1.93–2.22)
55–64 vs. 18–34	3.31 (3.07–3.58)	2.69 (2.35–3.09)	2.12 (1.97–2.28)
Sex (female vs. male)	1.41 (1.35–1.48)	2.29 (2.14–2.45)	1.96 (1.87–2.06)
Race (White vs. Nonwhite)	1.80 (1.66–1.95)	2.13 (1.88–2.41)	1.97 (1.81–2.14)
Medicaid pathway-to-eligibility (cash eligibility vs. others)	1.40 (1.32–1.49)	1.64 (1.51–1.81)	1.30 (1.22–1.38)

Definition-1 (new definition) is the simultaneous use of ≥5 different drug classes for a 60-day consecutive period; Definition-2 is the average number of drug classes that was 1 standard deviation above the mean in a 90-day period; Definition-3 is >5 different drug classes used in an arbitrary 90-day period.

AOR, adjusted odds ratio; CI, confidence interval.